Photocoagulation Treatment for Diabetic Retinopathy

In the 1950s, diabetic retinopathy, a complication of diabetes affecting the eyes, was a leading cause of blindness in the United States. A treatment called photocoagulation was introduced to manage this condition, but there was limited evidence of its actual benefits due to a lack of controlled clinical trials. To address this, the Diabetic Retinopathy Study (DRS) began in 1971, enrolling over 1,700 patients across 15 medical centers. This study is important as it aims to provide solid evidence on the effectiveness of photocoagulation in managing diabetic retinopathy, potentially improving care and reducing blindness for those affected by this condition. In this study, one eye of each patient is randomly chosen for immediate photocoagulation treatment, while the other eye is left untreated for comparison. The eye selected for treatment is then randomly assigned to one of two techniques, either using an argon laser or a xenon arc photocoagulator. Patients are monitored every 4 months, with their vision being carefully measured. The treatment typically involves one or two sessions and includes scatter photocoagulation, a procedure that extends to specific areas of the eye. The argon treatment involves a certain number of scatter burns and direct treatment of new vessels in specific areas, while the xenon technique involves fewer, stronger, and longer burns.